Sublingual Dexmedetomidine as a Potential New Treatment for Agitation
JAMA
.
2022 Feb 22;327(8):723-725.
doi: 10.1001/jama.2021.21313.
Author
John K Hsiao
1
Affiliation
1
National Institutes of Health, Bethesda, Maryland.
PMID:
35191943
DOI:
10.1001/jama.2021.21313
No abstract available
Publication types
Editorial
Comment
MeSH terms
Dexmedetomidine*
Humans
Hypnotics and Sedatives
Psychomotor Agitation
Substances
Hypnotics and Sedatives
Dexmedetomidine